gsk2256294

Small moleculeexperimental

Clinical trial activity

5 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Jan 16, 2013 (NCT01762774)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CNc1nc(C)nc(N[C@H]2CCC[C@@H](C(=O)NCc3ccc(C#N)cc3C(F)(F)F)C2)n1
Mol. weight
447.47 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • gsk2256294
  • gsk2256294
  • gsk2256294
  • n-((4-cyano-2-(trifluoromethyl)phenyl)methyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexanecarboxamide

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03486223Phase 2May 17, 2018National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Vanderbilt University
NCT03318783Phase 1/Phase 2 (Phase 2)May 2, 2018Oregon Health and Science University
NCT02262689Phase 1Jan 8, 2015GlaxoSmithKline, Parexel
NCT02006537Phase 1Jan 31, 2014GlaxoSmithKline
NCT01762774Phase 1Jan 16, 2013GlaxoSmithKline
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit3312013
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government1012018
National Institutes of Health (NIH)Government1012018
Oregon Health and Science UniversityAcademic/Hospital1112018
ParexelFor profit1012015
Vanderbilt UniversityAcademic/Hospital1112018
6 organizations
Page 1 / 1